This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Focus on: Ramadan
Prior to Ramadan, it is important to undertake medication reviews of your adult patients with type 2 diabetes who wish to fast during this time
Developed by Alia Gilani,
Senior Diabetes Clinical Pharmacist,
Primary Care Sheffield, Sheffield
Alia is a part-time Senior Diabetes Clinical Pharmacist for Primary Care Sheffield, whose interests lie in ethnic inequalities and diabetes. She helped to establish and run a bilingual medication review service in NHS Glasgow in 2002 and received local and national awards for this work. She has chaired the NHS Glasgow Diabetes Ethnicity and Inequalities Group in the past.
Alia has been running outreach clinics for South Asian people with diabetes for over a decade and was a member of the Diabetes Working Group for the South Asian Health Foundation (SAHF) for 13 years and had the role of Regional Lead and Chief Executive Officer for 2 years. She was the first pharmacist on the Primary Care Diabetes Society (PCDS) and a committee member for 7 years.
Supporting your patients during Ramadan
Ramadan fasting: A guide for adults with type 2 diabetes
Supporting your patients during Ramadan
The risks of fasting during Ramadan in adults with type 2 diabetes
Supporting your patients during Ramadan
Reference: Salti I et al. Diabetes Care 2004;27:2306–11
The event starts in:
Coming soon
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
This promotional website has been developed, organised and funded by Boehringer Ingelheim. Editorial support for this website has been provided by OmniaMed Communications.
PC-GB-106628 V5 | December 2023
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2023 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.